Gene Therapy for Neurological Disorders

NEURODEGENERATIVE DISEASES

Neurodegenerative diseases are a broad group of progressive disorders of the central nervous system (CNS) characterized by gradual loss of neuron structure and function. These disorders are typically chronic, incurable, and worsen with time.

Common Examples of Neurodegenerative Diseases

Disease	Major Site Affected	Key Clinical Feature
ALS (Amyotrophic Lateral Sclerosis)	Motor neurons	Paralysis (Loss of voluntary motor function), muscle wasting (progressive weakness, thinning of muscle mass, and impaired mobility)
FTD (Frontotemporal Dementia)	Frontal (decision-making, planning, personality, voluntary motor control, and social behavior) & temporal lobes (Brain regions responsible for memory, language comprehension, and auditory processing)	Personality & behavioral changes
SCAs (Spinocerebellar Ataxias)	Cerebellum	Gait and coordination defects
Huntington’s Disease (HD)	Basal ganglia (A group of subcortical nuclei that regulate movement and motor control)	Chorea (Rapid, involuntary, irregular movements of the limbs, face, or trunk), cognitive decline (A progressive deterioration in memory, thinking, and higher mental functions)
Alzheimer’s Disease (AD)	Cortex & hippocampus	Memory loss, dementia
Parkinson’s Disease (PD)	Substantia nigra (a brain structure in the midbrain that produces dopamine)	Tremor, rigidity, bradykinesia (Slowness of voluntary movement)

---

Epidemiology & Impact

• Age-Dependent Prevalence:
  Neurodegenerative diseases are predominantly age-related disorders, with incidence and prevalence rising sharply in individuals over 60–65 years. As global life expectancy increases, especially in developed and developing nations, the population of older adults is expanding. Consequently, the overall burden and frequency of neurodegenerative disorders are growing worldwide.

• Major Socioeconomic and Healthcare Burden:
  These disorders are chronic, progressive, and disabling, often requiring long-term medical care, rehabilitation, and continuous social and family support. This creates:

• Substantial economic strain on healthcare systems
• High direct medical costs (medications, hospitalizations, nursing care)
• High indirect costs (loss of productivity, caregiver burden, long-term disability)
• Diseases like Alzheimer’s and Parkinson’s are now among the leading causes of disability and dependency in the elderly, contributing significantly to the global health burden.

• Multifactorial Etiology, With Aging as the Dominant Risk Factor:
  Development of neurodegenerative diseases results from a complex interplay of genetic susceptibility, environmental exposures, and cellular aging mechanisms. Although specific gene mutations can cause familial forms, the majority of cases are sporadic (occur without a clear inherited (familial) genetic mutation and without a direct Mendelian pattern of transmission)

• Aging is the strongest and most consistent risk factor, as it is associated with:

• Accumulated cellular damage (oxidative stress (An imbalance between free radical production and antioxidant defenses), DNA damage)
• Impaired protein clearance
• Mitochondrial dysfunction
• Reduced neuroregenerative capacity
• Together, these changes make aging neurons more vulnerable to degeneration, explaining why risk increases dramatically in later decades of life.

---

Causes and Risk Factors of Neurodegenerative Diseases

A. Genetic Factors

• Gene Mutations and Polymorphisms:
  Specific genetic mutations can directly cause familial (inherited) forms of neurodegenerative diseases, while certain polymorphisms increase susceptibility to sporadic forms.

  • Examples:

• HTT gene (CAG expansion) in Huntington’s disease
• SNCA and LRRK2 mutations in Parkinson’s disease
• APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer’s disease
• SOD1, C9orf72, TARDBP in Amyotrophic Lateral Sclerosis

• Shared Molecular Pathways:
  Some mutations affect common cellular processes, such as protein folding, autophagy, or synaptic signaling, leading to overlapping mechanisms across different neurodegenerative diseases.
  → This explains why disorders such as ALS, FTD, and Alzheimer’s can share pathological features (e.g., TDP-43 aggregation).

---

B. Environmental and Lifestyle Factors

Environmental exposures and life experiences can act as external triggers that increase the risk of neurodegeneration, especially in genetically vulnerable individuals.

• Neurotoxic Exposures:

• Heavy metals (e.g., lead, mercury)
• Pesticides and industrial chemicals
• Air pollution

• Biological and Lifestyle Stressors:

• Chronic psychological stress
• Poor nutrition and metabolic disorders
• Infections that trigger neuroinflammation

• Social and Physical Factors:

• Social isolation or deprivation
• Physical trauma (e.g., repeated head injury → linked to Tau pathology)

These factors can contribute to chronic inflammation, oxidative stress, and cellular toxicity, ultimately making neurons more vulnerable.

---

C. Aging (The Most Critical Risk Factor)

Aging is the strongest and most universal risk factor for sporadic neurodegenerative diseases. As the brain ages, several degenerative cellular processes accelerate:

• Mitochondrial Dysfunction:
  Reduced energy production and increased free radical generation impair neuronal survival.

• Oxidative Stress:
  Accumulation of reactive oxygen species (ROS) leads to protein, lipid, and DNA damage.

• Loss of Proteostasis:
  Aging weakens the cellular machinery responsible for protein folding, repair, and clearance, promoting toxic protein aggregation (e.g., amyloid-β, Tau, α-synuclein).

• Impaired Neuroregeneration and Plasticity:
  Decline in neural stem cell function reduces the brain’s ability to repair, remodel, or replace damaged neurons.

Together, these age-related changes create a pro-degenerative environment, which explains why neurodegenerative disorders are predominantly late-life diseases.

---

Common Pathological Mechanisms in Neurodegenerative Diseases

Although neurodegenerative diseases differ in clinical presentation and primary anatomical targets, many of them share overlapping molecular and cellular mechanisms that ultimately lead to progressive neuronal dysfunction and death.

Pathological Mechanism	Examples of Diseases / Proteins Involved	Resulting Effect on the CNS
Protein Misfolding & Aggregation	- Amyloid-β, Tau (Alzheimer’s Disease) - α-synuclein (Parkinson’s Disease) - TDP-43 (Amyotrophic Lateral Sclerosis/ Frontotemporal Dementia) - Huntingtin (Huntington’s disease)	Toxic oligomers and aggregates disrupt synapses, impair neuronal signaling, and trigger cell death
Demyelination	- Multiple Sclerosis (MS) - Leukodystrophies	Loss of myelin slows or blocks action potential conduction, resulting in sensory and motor deficits
Loss of Axonal Integrity and Regeneration	- Amyotrophic Lateral Sclerosis, PD, traumatic and degenerative axonopathies	Impaired axonal transport and regeneration leads to progressive motor dysfunction and muscle weakness
Neuronal Cell Death (Apoptosis / Necroptosis)	Common to all major neurodegenerative disorders	Permanent loss of neural circuits, leading to irreversible cognitive, sensory, or motor impairment

---

Prion-Like Spread of Pathology

A key emerging concept is that many misfolded proteins behave in a prion-like manner, meaning they can:

• Self-propagate by converting normal proteins into misfolded forms
• Spread trans-synaptically from one neuron to another
• Progressively advance through neural networks, matching the clinical spread of symptoms

This mechanism has been described for Tau, α-synuclein, huntingtin, and TDP-43, helping explain the stepwise progression.

---

Breakdown of Proteostasis

Misfolded protein aggregates overwhelm the cellular quality-control systems, including:

• The ubiquitin-proteasome system (UPS)

• Autophagy-lysosomal pathways

• Chaperone-mediated folding systems

Failure of these pathways leads to a proteostasis collapse, resulting in:

• Accumulation of toxic proteins
• Mitochondrial dysfunction
• Oxidative stress
• Impaired synaptic communication

Ultimately, these events converge on neuronal dysfunction and degeneration.

---

Clinical Manifestations of Neurodegenerative Diseases

Although the specific symptoms of neurodegenerative disorders depend on which region of the brain, spinal cord, or peripheral nerves is primarily affected, most conditions exhibit a progressive decline in neurological function. Common clinical manifestations include:

1. Cognitive Impairment and Memory Loss

• Frequently seen in disorders affecting the cerebral cortex and hippocampus, such as Alzheimer’s disease and Frontotemporal dementia

• Features include:

  • Short-term memory deficits

  • Impaired executive function (planning, judgment, decision-making)

  • Disorientation and difficulty with learning new information

• In advanced stages, patients may progress to global dementia

---

2. Motor Dysfunction

• Characteristic of diseases involving the basal ganglia, cerebellum, motor cortex, or motor neurons

• Common manifestations:

  • Weakness and paralysis → e.g., ALS

  • Tremors, rigidity, bradykinesia → e.g., Parkinson’s disease

  • Ataxia and impaired coordination → e.g., Spinocerebellar ataxias

• These symptoms progressively impair mobility and daily activities

---

3. Behavioral and Psychiatric Changes

• Seen prominently in Frontotemporal dementia, but may occur in other disorders

• Manifestations include:

  • Personality changes

  • Apathy (reduced motivation), irritability (heightened emotional reactivity), impulsivity (Acting without forethought or consideration of consequences)

  • Depression, anxiety, mood swings, or psychosis (hallucinations)

---

4. Speech, Swallowing, and Respiratory Difficulties

• Result from degeneration of motor neurons, brainstem nuclei, or bulbar pathways

• Symptoms may include:

  • Dysarthria (slurred or slow speech)

  • Dysphagia (difficulty swallowing)

  • Respiratory muscle weakness → a major cause of mortality in ALS

---

5. Sensory and Autonomic Dysfunction

• More common in later stages or in diseases with peripheral or widespread CNS involvement

• Features may include:

  • Numbness, paresthesia (pins and needles), or loss of vibration and proprioception (Impaired ability to sense limb position or vibratory stimuli)

  • Bladder or bowel dysfunction

  • Orthostatic hypotension, altered sweating, or cardiac autonomic instability (Irregular heart rate or blood pressure control)

---

7. Disease Onset: The “Two-Hit” Hypothesis

• Pathology begins years before symptoms become clinically detectable.

• Early-life insults (infections, toxins, stress, malnutrition) may impair neuroplastic development.

• Later in life, aging or environmental triggers can produce the second hit, initiating symptoms.

---

8. Diagnostic Challenges

• Early symptoms are subtle and nonspecific → often mistaken for normal aging.

• Clinical overlap between diseases leads to misdiagnosis or delayed diagnosis.

• Major limitations:

  • Few biomarkers

  • Lack of early detection tools

  • Limited drug targets and delivery methods

---

9. Treatment Status

• Currently no curative therapy exists.

• Only palliative or symptomatic treatments are available.

• Aim of existing therapies:

  • Reduce symptoms

  • Improve quality of life

  • Slow progression (modestly, in some cases)

---

10. Need for Future Advances

There is an urgent need to:

• Understand molecular pathogenesis more clearly

• Identify early biomarkers

• Develop gene-based and disease-modifying therapies

• Improve targeted CNS delivery (e.g., across the blood–brain barrier)

---

11. Gene Therapy Focus

• Emerging gene therapies for diseases like ALS and SCA3 are showing promise.

• AAV (Adeno-associated viral) vectors are a leading delivery platform.

• Major translational challenges remain, especially in:

  • Targeting specific CNS regions

  • Long-term safety

  • Immune response

  • Large-scale clinical effectiveness

---

Amyotrophic Lateral Sclerosis (ALS)

• ALS, is the most common adult-onset motor neuron disease.
• It affects both upper motor neurons (UMNs) in the motor cortex and lower motor neurons (LMNs) in the brainstem and spinal cord.
• This dual involvement leads to progressive motor dysfunction, muscle wasting, and ultimately paralysis.
• Occasionally, other brain regions are also affected, linking ALS to broader neurodegenerative mechanisms.

Stephen Hawking’s symptoms were characteristic of the late stage of ALS and he was a rare case of decade-long ALS survival.

---

2. Pathophysiology

Neuron Type Affected	Location	Clinical Effect of Degeneration
Upper Motor Neurons	Motor cortex	Spasticity (increased muscle tone — the muscles are abnormally stiff or resistant to passive movement), hyperreflexia (overactive or exaggerated deep tendon reflexes (e.g., brisk knee jerk)
Lower Motor Neurons	Brainstem, spinal cord → muscles	Muscle weakness, cramps, paralysis

The disease causes irreversible degeneration of these motor pathways, leading to failure of voluntary muscle control.

---

3. Epidemiology

• Prevalence: ~5 per 100,000 people.
• Median survival: 2–5 years after symptom onset.
• Gender: Slight male predominance.
• Peak age of onset: 55–75 years.

---

4. Etiology and Risk Factors

• Familial ALS (≈10%): Inherited in an autosomal dominant pattern.
• Sporadic ALS (≈90%): No clear family history; aging is a major risk factor.

---

5. Major Genetic Mutations in ALS

More than 30 genes have been implicated.
The most common causes include mutations in:

Gene	Protein Encoded / Function	Key Notes
C9orf72	Unknown; may regulate autophagy-lysosome pathway	Most frequent cause
SOD1	Superoxide dismutase – antioxidant enzyme	First gene linked to ALS
TARDBP	regulates RNA processing and transport	Mislocalized from the nucleus to the cytoplasm of neurons and glial cells, where it forms abnormal aggregates. and aggregated in 97% ALS cases
FUS (Fused in Sarcoma gene)	RNA-binding protein involved in transcription and splicing	Found in some familial forms

---

6. The C9orf72 Hexanucleotide Repeat Expansion

• Mutation: GGGGCC (G4C2) repeat expansion in the first intron of the C9orf72 gene.
• Normal: ≤20–30 repeats; Pathogenic: >30 repeats.

---

7. Pathogenic Mechanisms in C9orf72-Related ALS

(a) RNA-Mediated Toxicity

• Expanded G4C2 RNA forms abnormal secondary structures.
• These structures bind and sequester RNA-binding proteins (e.g., TDP-43, FUS, hnRNPA1), impairing their normal function.
• Results in defective RNA splicing, transport, and processing, leading to neurodegeneration.

(b) RAN (Repeat-Associated Non-ATG) Translation

• Abnormal translation of repeat-containing RNA without an ATG start codon.

• Produces toxic

  dipeptide repeat (DPR) proteins

  , such as:

• Poly-GA (Glycine–Alanine)
• Poly-GP (Glycine–Proline)
• Poly-GR (Glycine–Arginine)
• Poly-PR (Proline–Arginine)
• Poly-PA (Proline–Alanine)
• These DPRs:
• Form aggregates in neurons and glia.
• Impair nuclear transport, and RNA processing.
• Cause TDP-43 cytoplasmic mislocalization, a hallmark of ALS pathology.

---

8. Clinical Features

Feature Type	Description
Motor Symptoms	Progressive weakness, spasticity, muscle wasting, paralysis
Bulbar (mouth, pharynx, larynx, and tongue) Symptoms	Dysarthria (nasal speech due to weakness of tongue), dysphagia, tongue atrophy
Respiratory Involvement	Respiratory failure (main cause of death)

9. Diagnosis

• Clinical: Progressive UMN + LMN signs in multiple regions.
• MRI
• Genetic testing

---

10. Treatment and Prognosis

Therapy	Mechanism / Effect	Limitation
Riluzole (1995)	Glutamate receptor antagonist (blocks the action of glutamate, the main excitatory neurotransmitter)	Extends survival by 2–3 months
Edaravone (2017)	Free radical scavenger (antioxidant)	Modest benefit; slows decline in some patients

Supportive care:

• Non-invasive ventilation, physiotherapy, nutritional support are critical.

---

11. Future Directions

• Antisense oligonucleotides (ASOs) and RNA interference (RNAi) approaches are being developed to silence mutant C9orf72 RNA or block DPR translation.
• Other strategies include gene therapy, neuroprotective compounds, and stem cell–based regeneration.

---

Parkinson’s Disease (PD)

• Parkinson’s disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (a pigmented region of the midbrain that plays a key role in motor control).
• The resulting dopamine deficiency in the basal ganglia leads to motor dysfunction.

---

2. Key Clinical Features (Motor Symptoms)

Symptom	Description
Bradykinesia	Slowness of movement (main diagnostic hallmark)
Rigidity	Muscle stiffness and resistance to movement
Tremor	Typically a resting tremor ("pill-rolling")
Postural instability / Gait dysfunction	Balance problems, shuffling gait, falls

🩺 other symptoms are Facial masking (reduced facial expression due to decreased facial muscle movement), Reduced arm swing (diminished automatic arm movement during walking), Micrographia (abnormally small, cramped handwriting), Hypophonia (soft or low-volume speech).

---

3. Pathophysiology

1. Degeneration of dopaminergic neurons:

   • In Parkinson’s disease (PD), the dopamine-producing neurons in the substantia nigra pars compacta (a part of the midbrain) gradually die.

   • These neurons normally send dopamine to the striatum (which includes the caudate nucleus and putamen) — regions of the brain that help control movement.

2. Reduced dopamine levels:

   • As these neurons degenerate, the dopamine level in the striatum decreases.

   • Dopamine acts as an inhibitory neurotransmitter that balances the excitatory signals from acetylcholine (Excess excitation of motor circuits, Resting tremor, Rigidity)

3. Lewy bodies:

   • Inside the dying neurons, abnormal clumps called Lewy bodies appear.

   • These contain a misfolded protein called α-synuclein, which disrupts cell function and contributes to neuronal death.

4. Neurochemical imbalance:

   • The loss of dopamine means the excitatory influence of acetylcholine becomes unopposed.

   • This imbalance between dopamine (inhibitory) and acetylcholine (excitatory) leads to abnormal signaling in the basal ganglia, the brain region controlling smooth and coordinated movements.

---

4. Neurotrophic Factor-Based Gene Therapy

Aim / Concept:

• The goal of this approach is not to fix the underlying genetic or molecular defect causing Parkinson’s disease.
• Instead, it focuses on supporting the survival and function of the remaining dopaminergic neurons — essentially slowing disease progression.

Neurotrophic Factors Used:


• Glial Cell-Derived Neurotrophic Factor (GDNF) and Neurturin (NTN) are naturally occurring proteins that help protect and nourish neurons, especially dopaminergic ones.
• These factors were delivered using Adeno-Associated Virus (AAV) vectors.

Delivery Method:


• The therapy involves direct intraparenchymal injection, meaning the vector carrying the gene for GDNF or NTN is injected straight into the brain tissue (usually the putamen or substantia nigra).
• This ensures the neurotrophic factor is produced locally where neurons need support.

Clinical Results:


• Safety: The therapy was found to be safe and well-tolerated, with no major adverse effects.
• Efficacy: Clinical benefit (improvement in motor symptoms) was inconsistent or limited — so, while the biological approach is sound, it didn’t show strong clinical improvement in trials.
• Significance: The studies proved that targeted gene delivery into human brain tissue is feasible, which is an important step for future therapies.

---

5. Gene Therapy to Restore Dopamine Production

Goal: Re-establish dopamine synthesis in neurons by delivering dopamine-synthesizing enzymes.

🧬 Key Enzyme: Aromatic L-Amino Acid Decarboxylase (AADC)

• Converts L-DOPA → dopamine.

• AAV-AADC gene delivery has shown:

• ↑ dopamine levels (sustained up to 7 years in primates).
• Improved Unified Parkinson’s Disease Rating Scale (UPDRS) scores in human trials.
• Good safety profile, mild side effects.

---

6. Multienzyme Gene Therapy (ProSavin and Similar Approaches)

• ProSavin: Lentiviral vector delivering three dopamine-synthesis genes:

1. Tyrosine hydroxylase (TH) – converts tyrosine → L-DOPA
2. AADC – converts L-DOPA → dopamine
3. GTP cyclohydrolase-1 – cofactor synthesis for TH

• Delivered intrastriatally for continuous dopamine production.

• Results:

• Safe and well-tolerated.
• Improved motor function.
• Ongoing long-term follow-up.

🔬 Next-generation lentiviral therapy (NCT03720418)

• Similar to ProSavin but optimized for higher dopamine production.

• Preclinical studies show enhanced efficacy in human neurons and non-human primates (NHPs).

---

Alzheimer’s Disease (AD)

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of age-related dementia. It primarily affects memory, cognition (collection of mental processes by which the brain acquires, stores, processes, and uses information. These processes allow humans to understand the world, think, learn, remember, solve problems, and make decisions), and behavior due to widespread neuronal loss and synaptic dysfunction.

Epidemiology

• The prevalence increases sharply with age.

• More than 40% of individuals aged 85 years or older are affected.

• AD represents a major public health burden, with no available cure or disease-modifying therapy.

Current therapeutic challenge

• Although over 100 therapeutic compounds have been tested in clinical trials—including drugs targeting amyloid (beta-pleated sheet structure, making them insoluble, resistant to degradation, and capable of forming extracellular deposits), tau (maintaining neuronal structure and axonal transport), inflammation, metabolism, and synaptic transmission—none have been able to modify the progression of AD.

• Available treatments (e.g., acetylcholinesterase inhibitors, NMDA antagonists (block NMDA (N-methyl-D-aspartate) receptors, a type of glutamate receptor found widely in the brain.)) offer only symptomatic relief.

Pathological basis

• Accumulation of amyloid-β plaques.

• Formation of intracellular aggregates of abnormally modified tau protein due to hyperphosphorylated tau.

• Loss of cholinergic neurons in the basal forebrain.

• Chronic neuroinflammation and oxidative injury (e.g., superoxide, hydrogen peroxide, hydroxyl radicals).

---

Gene Therapy Approaches in AD

Gene therapy for AD aims to provide neuroprotective molecules or genetically modify risk pathways. These strategies mainly use AAV (Adeno-Associated Virus) vectors, which are well-suited for delivery into the CNS due to their stability, low immunogenicity, and ability to infect neurons.

---

1. AAV-NGF (Nerve Growth Factor) Delivery

Concept

• NGF is a neurotrophic factor (support the growth, survival, and differentiation of neurons) required for survival and function of cholinergic neurons in the basal forebrain.

• These neurons are among the earliest and most severely affected in AD.

• NGF is structurally and functionally related to Glial Cell-Derived Neurotrophic Factor (GDNF) and Neurturin (NTN), which also support neuronal survival.

Delivery method

• Intracerebral delivery through stereotactic surgery (a minimally invasive surgical technique that allows precise targeting of specific areas of the brain using a three-dimensional coordinate system. Combines imaging (MRI, CT)).

• AAV vectors are injected directly into brain regions where cholinergic neurons are located.

Rationale (Why NGF?)

• NGF can:

  • Support neuron survival.

  • Enhance cholinergic neurotransmission.

  • Potentially slow degeneration of memory-related neural circuits.

Preclinical findings

• In animal models, NGF delivery prevented degeneration of adult basal forebrain cholinergic neurons after injury.

• Demonstrated strong neuroprotective effects in rodents and primates.

Clinical trial outcomes

• Early human trials showed:

  • Surgical delivery was safe.

  • NGF expression was detectable in targeted brain areas.

  • No major adverse events from gene transfer.

• However, results on cognitive improvement or slowing of disease progression do not provide clear evidence to confirm or reject a hypothesis.

• Overall, the therapy was feasible and safe but not proven effective.

---

2. AAVrh.10-APOE2 Delivery (Trial: NCT03634007)

Rationale: Genetics of APOE in AD

• APOE encodes apolipoprotein E, a key protein in lipid transport and amyloid metabolism.

• Three common alleles exist: APOE2, APOE3, APOE4.

• APOE4 significantly increases the risk of sporadic AD and is associated with earlier onset.

• APOE2 appears protective, reducing risk and delaying onset.

Hypothesis

• Delivering APOE2 into the CNS of individuals who are APOE4 homozygous might:

  • Counteract the harmful effects of APOE4.

  • Improve amyloid clearance.

  • Reduce neuroinflammation.

  • Potentially modify the disease course.

Gene therapy strategy

• Vector: AAVrh.10, a serotype that efficiently transduces CNS tissue.

• Route: Intracisternal delivery, allowing widespread distribution of the vector in the brain.

• Treatment goal: Introduce additional APOE2 copies to shift the biological environment toward a protective state.

Current status

• Early results: The therapy has shown safety in initial phases.

• Actual impact on AD progression is still undetermined, and long-term efficacy data are not yet available.

• This approach remains experimental but represents a promising shift toward genotype-based personalized therapy.

---

Huntington’s Disease (HD)

• HD is the most common autosomal dominant neurodegenerative disorder worldwide.

• Prevalence: ~5–10 per 100,000 in populations of European descent; lower in Asian populations.

• Onset: Typically between 30–50 years, though juvenile forms exist.

• Course: Progressive, leading to severe motor, cognitive, and psychiatric impairment and premature death.

---

Genetic Basis

• Causative gene: Huntingtin (HTT) gene, located on chromosome 4p16.3.

• Mutation: Expansion of CAG trinucleotide repeats in exon 1 of HTT.

  • Normal allele: <36 CAG repeats → non-pathogenic.

  • Pathogenic allele: ≥39 CAG repeats → causes HD.

• Mechanism: The mutation leads to polyglutamine (polyQ) expansion in HTT protein, resulting in toxic gain-of-function.

• Inheritance: Autosomal dominant → 50% risk to offspring of affected parent.

---

Molecular Pathophysiology

1. Mutant HTT Protein

   • Misfolded protein forms intracellular aggregates and inclusion bodies.

   • Disrupts proteostasis (cellular processes that maintain the proper synthesis, folding, trafficking, and degradation of proteins), transcription, mitochondrial function, axonal transport, and synaptic signaling.

   • Generates highly toxic exon 1 HTT fragments (short protein or mRNA segments derived from the first exon of the huntingtin (HTT) gene) that exacerbate neuronal injury.

2. Selective Vulnerability

• Medium spiny neurons (MSNs) of the striatum are affected early → motor dysfunction.

• Cortical neurons degenerate later → cognitive decline.

• Other brain regions may also be affected in advanced stages.

1. Cellular Consequences

   • Excitotoxicity: Dysfunctional glutamate signaling → neuronal death.

   • Mitochondrial dysfunction: Reduced ATP, increased oxidative stress.

   • Transcriptional dysregulation: Abnormal gene expression in neurons.

   • Impaired protein degradation: Proteasome and autophagy pathways overwhelmed.

---

Clinical Features

1. Motor Symptoms

   • Chorea (involuntary, jerky movements).

   • Dystonia, bradykinesia (slowness of voluntary movement), and rigidity in later stages.

   • Impaired coordination, gait abnormalities.

2. Cognitive Symptoms

   • Executive dysfunction: impaired planning, problem-solving.

   • Memory deficits, attention deficits.

   • Decline in learning abilities.

3. Psychiatric Symptoms

   • Depression, irritability, anxiety.

   • Apathy and social withdrawal.

   • Psychosis in some patients.

---

Current Treatment

• No therapy halts disease progression; treatment is symptomatic:

  • Tetrabenazine: reduces chorea.

  • Antidepressants, antipsychotics: manage psychiatric symptoms.

  • Supportive care: physiotherapy, speech therapy, occupational therapy.

---

Gene Therapy Approaches

1. Antisense Oligonucleotides (ASOs)

• Mechanism: Synthetic nucleic acids bind HTT mRNA → reduce translation of both wild-type and mutant protein.

• Delivery: Intrathecal injection into cerebrospinal fluid (CSF).

• Clinical Trials:

  • IONIS Pharmaceuticals (NCT02519036, Phase I/II, 2015)

    • Reduced HTT in CSF; safe.

  • Roche Phase III (NCT03761849, 2018–ongoing)

    • Large multicenter trial (~80–90 sites, 15 countries).

    • Concerns: whether ASO reaches deep brain regions like striatum.

    • Observed dose- and time-dependent ventricular enlargement, suggesting possible CNS atrophy.

2. AAV-Based RNAi Therapy

• Therapy: AMT-130 (AAV5-miHTT)

  • Encodes anti-HTT miRNA targeting exon 1 region of HTT mRNA.

  • Injected directly into striatum → long-term miHTT production.

• Advantages:

  • Long-lasting, localized effect.

  • Can target toxic exon 1 mRNAs.

• Preclinical Data:

  • Q175FDN mouse model: dose-dependent reduction of exon 1 HTT mRNA in striatum and cortex.

• Clinical Trial:

• uniQure (NCT04120493, 2019): first two patients treated; ongoing evaluation.

---

1. Spinocerebellar Ataxias (SCAs)

• SCAs = A group of autosomal-dominant neurodegenerative diseases.

• Characterized by:

  • Progressive cerebellar ataxia (loss or impairment of coordinated voluntary movements) → impaired balance, gait, coordination, speech.

• Prevalence: 1–3 per 100,000, varies by region/ethnicity.

• More than 40 types identified.

• Most common polyglutamine (polyQ) SCAs:

  • SCA1, SCA2, SCA3, SCA6, SCA7, SCA17
    → All caused by CAG repeat expansions.

---

2. What is SCA3 (Machado-Joseph Disease)?

• Most common SCA worldwide.

• Also the second most common polyQ disease after Huntington’s disease (HD).

• Genetic cause: Expanded CAG repeat in ATXN3 gene (chromosome 14q32.1).

• Disease severity correlates with repeat length.

CAG Repeat Range

CAG Repeats	Interpretation
≤ 44	Normal
45–51	Intermediate
> 51	Pathogenic (SCA3)

• Life expectancy: 10–21 years after symptom onset.

---

3. Clinical Features of SCA3

SCA3 affects multiple systems.

Most common symptoms

• Progressive ataxia (balance, gait, coordination)

• Dysarthria (Imprecise, slow, or unclear articulation of words, due to poor control or weakness of the muscles used for speech)

• Dysphagia (difficulty swallowing)

• Rigidity and stiffness

• External ophthalmoplegia (impaired eye movements)→ difficulty looking in certain directions.

• Double vision

• Distal muscle atrophy

---

4. ATXN3 Gene and Ataxin-3 Protein

Structure

Ataxin-3 = 42 kDa protein with:

1. N-terminal Josephin domain (catalytic)

2. C-terminal ubiquitin-interacting motifs (UIMs)

3. PolyQ tract (location of expanded repeat)

Normal Function

Ataxin-3:

• Modifies ubiquitin chains on proteins, and participates in protein quality control.

• Roles in:

  • ER-associated degradation (ERAD)

  • Protection from misfolded proteins.

Expression

• Found in nucleus and cytoplasm.

• Present in many peripheral and neuronal tissues.

---

5. Mechanisms of Toxicity in SCA3

There are two major toxic mechanisms:

---

A. Toxic Gain-of-Function (Protein-Based Mechanism)

1. Expanded polyQ tract → misfolded ataxin-3

• Mutant ataxin-3 aggregates inside neurons.

• Aggregates contain:

  • Wild-type and mutant ataxin-3

  • Transcription factors

2. Why are aggregates toxic?

• They sequester essential proteins, disrupting:

  • Transcription

  • Protein degradation

3. Proteolytic cleavage produces short polyQ fragments

• These fragments are highly toxic, more prone to aggregation.

• Seen in cell models, mouse models, Drosophila, and patient tissues.

4. Altered ataxin-3 function

• PolyQ expansion alters:

  • Normal binding partners

  • Enzymatic function in ubiquitin pathways

---

B. RNA-Mediated Toxicity

Expanded CAG repeats in mRNA can:

• Sequester RNA-binding proteins

• Undergo RAN translation (Repeat-Associated Non-AUG translation)→ toxic polyAla, polySer peptides.

Evidence

• In C. elegans, long CAG repeats (in 3' UTR) caused:

  • Severe toxicity

  • Embryonic lethality (very long repeats)

  • RNA foci formation

Thus, both protein and RNA toxicity contribute to SCA3.

* The 3' UTR is the section of mRNA located immediately after the stop codon and before the poly(A) tail. It is not translated into protein but plays essential regulatory roles.

---

6. Current Treatment Options

There is no cure.

Symptomatic treatments

• Antispasmodics (reduce spasticity)

• Speech therapy (s an essential supportive treatment for patients with ataxia, bulbar weakness, or neurodegenerative diseases)

• Physiotherapy

Drugs tested but ineffective

• Sulfamethoxazole-trimethoprim (tested for potential neuroprotective effect)

• Lithium carbonate (Neuroprotective, modulates protein aggregation)

Gene-Silencing Approaches Under Study

• Antisense oligonucleotides (ASOs): They bind to target mRNA through complementary base pairing and then: ↓ mutant ATXN3 mRNA → ↓ toxic ataxin-3 protein

• RNA interference (RNAi): mRNA is cleaved and destroyed →↓ mutant ataxin-3 protein

• Aim: lower mutant ATXN3 expression

---

RNAi-Based Therapeutic Strategies for Neurodegenerative Diseases

RNAi is a gene-silencing technology that reduces expression of disease-causing genes.
RNAi function:

• Naturally occurring in eukaryotes.
• Plays role in gene regulation and innate immune defense against viruses/bacteria.
• Mediated by the RNA-induced silencing complex (RISC), which cleaves mRNA.

2. Small Non-Coding RNAs in RNAi

• miRNAs, siRNAs:

  • miRNAs & siRNAs → negative regulators of gene expression.

---

miRNA Biogenesis

1. Transcription (Nucleus)

• miRNA genes are transcribed mainly by RNA Polymerase II.

• This produces a long primary transcript called pri-miRNA, which:

  • is several hundred nucleotides long,

  • contains a stem–loop (hairpin) structure,

  • resembles mRNA (5′ cap + poly-A tail).

2. Nuclear Processing by Drosha–DGCR8

• The Drosha enzyme (RNase III type) partners with DGCR8 (Pasha) to form the Microprocessor complex.

• Function: converts long transcript → short hairpin suitable for export.

3. Export to Cytoplasm (Exportin-5)

• Function: moves precursor from nucleus to cytoplasm for further processing.

---

4. Cytoplasmic Processing by Dicer

• In cytoplasm, Dicer (another RNase III enzyme) binds the pre-miRNA.

• This duplex has one strand destined to be the functional miRNA.

Function: creates the mature miRNA duplex.

---

5. RISC Loading

• The duplex is loaded onto the RISC (RNA-Induced Silencing Complex).

• AGO (Argonaute) proteins are the core of RISC.

• AGO selects one strand (the guide strand) 

Function: generates the active miRNA-RISC complex.

6. Target Recognition and Gene Silencing

• The mature miRNA within RISC binds complementary sites on mRNA, typically in the 3′ UTR.

a) Partial complementarity (most common in humans)

→ Translational repression
→ mRNA destabilization
→ Reduced protein production

b) Near-perfect complementarity

→ mRNA cleavage and degradation (more common in plants)

---

4. RNAi Therapeutics in Clinical Trials

• AMT-130 (AAV-miRNA for Huntington’s disease):

  • Targets mutant & wild-type Huntingtin mRNA.

  • Delivered via MRI-guided convection-enhanced stereotactic neurosurgery into striatum.

  • Phase I/II ongoing in 26 patients.

• Potential: Applicable for SCA, ALS, FTD, Parkinson’s, tauopathies, AD.

---

5. Alternative Silencing Strategies

A. Antisense Oligonucleotides (ASOs)

• Structure: Short single-stranded nucleotides (20–25 bases).

• Mechanisms:

  • RNase H-mediated mRNA degradation.

  • Steric blocking of splicing or translation.

• Clinical Examples:

  • ALS (SOD1, C9orf72) – Phase I/II trials ongoing.

  • Duchenne Muscular Dystrophy (DMD) – exon 51 skipping.

  • Limitations: rapid degradation → repeated administration, invasive delivery, BBB challenges.

B. Gene Editing (CRISPR/Cas9, ZFNs, TALENs)

• Mechanism: Sequence-specific DNA double-strand breaks → strand breaks (DSBs). Once a DSB occurs, cells repair DNA.

• Nucleases:

  • ZFNs, TALENs, CRISPR/Cas9

• Applications in Neurodegeneration:

  • Alzheimer’s Disease: Edited APP gene (Amyloid Precursor Protein) → reduced amyloid-beta.

  • ALS (Amyotrophic Lateral Sclerosis): Deleted G4C2 repeat in C9orf72.

  • HD (Huntington’s Disease): Suppressed mutant Huntingtin in mice.

  • SCA3 (Spinocerebellar Ataxia Type 3): Deleted CAG repeats in ATXN3.

---

6. AAVs for CNS Gene Transfer

• Challenges: BBB limits systemic delivery of therapeutic molecules.

• Delivery methods:

  1. Intracerebral: Precise, high local dose, minimal systemic exposure; invasive.

  2. Systemic (IV): Less invasive, but low CNS uptake.

  3. Intrathecal: Bypasses BBB, lower invasive risk, but limited deep brain transduction.

---

7. Gene Therapy Clinical Trials 

Disease	Vector	Delivery	Phase	Sponsor
Huntington’s Disease	AAV5-miHTT	Striatum	I/II	uniQure Biopharma
Parkinson’s (AADC deficiency)	AAV2-hAADC	Intraparenchymal	I/II	National Taiwan University
Alzheimer’s	AAV2-NGF	Basal forebrain	I/II	Sangamo/Ceregene